Cargando…

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

Aberrant activation and mutation status of proteins in the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen activated protein kinase (MAPK) signaling pathways have been linked to tumorigenesis in various tumors including urothelial carcinoma (UC). However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nawroth, Roman, Stellwagen, Florian, Schulz, Wolfgang A., Stoehr, Robert, Hartmann, Arndt, Krause, Bernd J., Gschwend, Juergen E., Retz, Margitta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216974/ https://www.ncbi.nlm.nih.gov/pubmed/22110663 http://dx.doi.org/10.1371/journal.pone.0027509

Ejemplares similares

Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer
por: Wagner, Julia, et al.
Publicado: (2022)

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
por: Sathe, Anuja, et al.
Publicado: (2018)

Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
por: Thalgott, Mark, et al.
Publicado: (2015)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer
por: Tong, Zhichao, et al.
Publicado: (2019)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
por: Thalgott, Mark, et al.
Publicado: (2014)

Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study
por: Schmid, Sebastian C., et al.
Publicado: (2015)

[(11)C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy
por: Schwarzenböck, Sarah M., et al.
Publicado: (2016)

Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells
por: Suttmann, Henrik, et al.
Publicado: (2008)

KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
por: Lunger, Lukas, et al.
Publicado: (2020)

STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
por: Hindupur, Sruthi V., et al.
Publicado: (2020)

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2017)

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study
por: Rogler, Anja, et al.
Publicado: (2014)

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians
por: Stoehr, Christine G., et al.
Publicado: (2012)

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
por: Keck, Bastian, et al.
Publicado: (2013)

DICER1-Mutated Botryoid Fibroepithelial Polyp of the Parotid Duct: Report of the First Case
por: Erber, Ramona, et al.
Publicado: (2021)

Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)
por: Schmid, Sebastian C., et al.
Publicado: (2020)

HLA-E expression and its clinical relevance in human renal cell carcinoma
por: Seliger, Barbara, et al.
Publicado: (2016)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms
por: Lewerich, J., et al.
Publicado: (2022)

Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer
por: Otto, Wolfgang, et al.
Publicado: (2012)

YAP1-MAML2-Rearranged Poroid Squamous Cell Carcinoma (Squamoid Porocarcinoma) Presenting as a Primary Parotid Gland Tumor
por: Agaimy, Abbas, et al.
Publicado: (2020)

Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort
por: Weyerer, Veronika, et al.
Publicado: (2021)

TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers
por: Weyerer, Veronika, et al.
Publicado: (2021)

New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21–23, 2017
por: Black, Peter C., et al.
Publicado: (2018)

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy
por: Eckstein, Markus, et al.
Publicado: (2018)

Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection
por: Lehmann, Jan, et al.
Publicado: (2002)

Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer
por: Eckstein, Markus, et al.
Publicado: (2021)

TERT Core Promotor Mutations in Early-Onset Bladder Cancer
por: Giedl, Johannes, et al.
Publicado: (2016)

Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade
por: Burger, M, et al.
Publicado: (2007)

Role of miRs in immune suppression
por: Seliger, Barbara, et al.
Publicado: (2014)

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
por: Wang, Li, et al.
Publicado: (2015)

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma
por: Erlmeier, F., et al.
Publicado: (2016)

Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer
por: Wu, Qiong, et al.
Publicado: (2005)

Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer
por: Breyer, Johannes, et al.
Publicado: (2017)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

RanBP3 enhances nuclear export of active β-catenin independently of CRM1
por: Hendriksen, Jolita, et al.
Publicado: (2005)

CK1BP Reduces α-Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation
por: Elsholz, Lea, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5bmqle02cvkbm2lfaqtuts0jjn